Aurobindo Pharma has reported results for third quarter ended December 31, 2024 (Q3FY25).
The company has reported 24.32% decline in its net profit at Rs 472.05 crore for Q3FY25 as compared to Rs 623.77 crore for the same quarter in the previous year. Total income of the company decreased marginally by 1.73% at Rs 2970.89 crore for Q3FY25 as compared to Rs 3023.30 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 10.04% decline in its net profit at Rs 845.57 crore for the quarter ended December 31, 2024 as compared to Rs 939.97 crore for the same quarter in the previous year. However, total income of the company increased by 8.27% at Rs 8135.81 crore for Q3FY25 as compared to Rs 7514.30 crore for the corresponding quarter previous year.
